We're #hiring a new Material Planner Clinical Trials (m|f|d) in Bergisch Gladbach, North Rhine-Westphalia. Apply today or share this post with your network.
Miltenyi Biomedicine
Arzneimittelherstellung
Bergisch Gladbach, North Rhine-Westphalia 3.257 Follower:innen
Developing personalized cell and gene therapies
Info
Miltenyi Biomedicine is a biopharmaceutical company that develops innovative cell and gene therapies. We are committed to bring cancer treatments and regenerative therapies to patients with unmet medical needs worldwide. We work in partnership with physicians and other healthcare providers to expand access to new therapies. Our clinical research program includes: CAR T, CAR NK, our proprietary Adapter CAR™ and induced pluripotent stem cells (iPSC) technologies. For more information, please visit our website at www.miltenyibiomedicine.com.
- Website
-
http://www.miltenyibiomedicine.com
Externer Link zu Miltenyi Biomedicine
- Branche
- Arzneimittelherstellung
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Bergisch Gladbach, North Rhine-Westphalia
- Art
- Privatunternehmen
- Gegründet
- 2019
- Spezialgebiete
- Clinical Applications, Clinical Development, Clinical Trials, CAR-T cells, Gene Therapy, Cell therapy, Immunology, Stem Cell Research, Cancer Research, CAR-T Technology, Immunotherapy, Autologous T cells, Research, Innovation, Innovative Therapies, Personalized Cell and Gene Therapies, Hematological Cancers, Optimizing Patient Outcomes, Fresh Cells Approach und Biopharma
Orte
-
Primär
Wegbeschreibung
Friedrich-Ebert Straße 68
Bergisch Gladbach, North Rhine-Westphalia 51429, DE
-
Wegbeschreibung
120 Beacon St
Suite 200
Somerville, Massachusetts 02143, US
Beschäftigte von Miltenyi Biomedicine
-
Wim Weyenberg
Biopharmaceutical Executive & Advisor | Medical & Clinical Affairs - Product Development & Life Cycle Management
-
Jörg Mahlich
Economist | Lecturer l Pharmaceutical Industry Expert
-
Donald Fitch
Biopharma Development and Operations Leader
-
Anna Wijatyk, MD
Chief Medical Officer, USA at Miltenyi Biomedicine
Updates
-
#EHA2024 is ongoing. We are committed to developing CAR-T cell therapies. If you want to find out more about our clinical portfolio, come and speak with our medical team at #MiltenyiBiomedicine booth D03
-
-
#EHA2024 is ongoing. We are committed to developing CAR-T cell therapies. If you want to find out more about our clinical portfolio, come and speak with our medical team at #MiltenyiBiomedicine booth D03
-
-
#EHA2024 is just a few hours away. If you want to find out more about our clinical portfolio, come and speak with our medical team at #MiltenyiBiomedicine booth D03
-
-
Will you be attending the #EHA2024 Congress in Madrid? Come to meet our Medical Advisors at booth D03. #MiltenyiBiomedicine
-
-
We are excited to be present at the #EHA2024 congress in Madrid and look forward to welcoming you to our booth D03. Come to speak to our medical team about our clinical program and CAR-T therapies. #MiltenyiBiomedicine
-
-
#EBMT24 is ongoing. We are committed to developing CAR-T cell therapies. If you want to find out more about our clinical portfolio, come and speak with our medical team at #MiltenyiBiomedicine booth E11
-
-
#EBMT24 is ongoing. Come and meet our medical team at booth E11 #MiltenyiBiomedicine #cartcelltherapy
-
-
Are you attending the #EBMT24 Congress in Glasgow? Come to meet our Medical Advisors at booth E11. #MiltenyiBiomedicine
-
-
We are excited to be present at the #EBMT24 Congress, in Glasgow. We look forward to welcoming you to our booth (E11), where you will be able to speak to our medical team about our clinical program and open trials. #MiltenyiBiomedicine
-